Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Research tools

WWL70

Synthetic ABHD6 inhibitor: it slows a secondary route of 2-AG degradation. A laboratory tool.

Unscheduled
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₇H₂₃N₃O₃

CID 17759121

Family
ECS pharmacological toolEnzyme inhibitor
Molar mass
437.50 g/mol

Updated on

In plain terms

WWL70 is a molecule made in the laboratory, absent from hemp. It blocks a body enzyme, ABHD6, that partly destroys 2-AG, a cannabinoid the body makes itself, which lets the latter act longer where it is released. It has been studied only on cells and animals; no study in humans was found.

Receptors and activity

Target network

MAGLInhibitorNo significant effect on 2-AG hydrolysis at 10 µM (transfected homogenates; Marrs et al. 2010)
  • Blocks or inhibits

The lower the cited value, the closer the target sits to WWL70: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of WWL70.

Brain, side view
Body, front view
Blood

MAGLMAGL found in 5 regions of the body

  1. CortexdenseHighest PET signal in the cerebral cortex1
  2. Basal gangliapresentModerate levels in the putamen1
  3. HippocampuspresentAxon terminals in the hippocampus2
  4. Adipose tissuepresentPresent in subcutaneous adipose tissue3
  5. Immune cellspresentRNA enhanced in blood monocytes4

Map sources

  1. Takahata K et al. First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with (18)F-T-401. Eur J Nucl Med Mol Imaging, 2022 (new tab)
  2. Ludányi A et al. Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience, 2011 (new tab)
  3. Spoto B et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie, 2006 (new tab)
  4. Human Protein Atlas. MGLL expression summary (new tab)

Cited values

  1. ABHD6InhibitorIC50 = 285 nM · human42 out of 100

    Shields et al., Sci Rep 2019 (new tab) · truncated recombinant human ABHD6, fluorogenic substrate AHMMCE; 70 nM by competitive activity-based profiling (mouse brain membranes, Li et al. 2007 as reported by Shields et al.); covalent inhibition (Ser148)

  2. MAGLInhibitorno measured value cited

    No significant effect on 2-AG hydrolysis at 10 µM (transfected homogenates; Marrs et al. 2010)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

WWL70 is a carbamate that covalently inhibits α/β-hydrolase domain 6 (ABHD6), a membrane serine hydrolase that contributes to the hydrolysis of 2-arachidonoylglycerol. Its IC50 is 70 nM in competitive activity profiling (mouse brain membranes, Li et al. 2007, value quoted by Shields et al.) and 285 nM on recombinant human ABHD6 with a fluorogenic substrate (Shields et al. 2019). At 10 µM, monoacylglycerol lipase was not significantly affected, and WWL70 did not interact directly with CB1 or CB2; its inhibition of ABHD6 let 2-AG accumulate depending on neuronal activity (Marrs et al. 2010). In mice, WWL70 improved motor or behavioural parameters and reduced inflammatory markers in models of traumatic brain injury, experimental multiple sclerosis and neuropathic pain (Tchantchou and Zhang 2013; Wen et al. 2018). Interpretation calls for caution: in neuropathic pain, the effects were not reversed by cannabinoid antagonists (Wen et al. 2018); in microglia, the reduction in PGE2 production was not reproduced by ABHD6 knockdown with siRNA nor by another inhibitor, KT182, which points to an off-target effect on COX-2 and PGES (Tanaka et al. 2017); and a 2018 re-evaluation concludes that blocking ABHD6 has modest therapeutic effects in experimental autoimmune encephalomyelitis, the protective effects of WWL70 on cultured neurons not being attributable to ABHD6 (Manterola et al. 2018). No study in humans was found.

Key sources.

History

Source
A synthetic molecule, absent from cannabis and from any living organism, known only as a research compound used to inhibit ABHD6 (Marrs et al. 2010).

Origin

Research tool

No natural biosynthetic pathway: WWL70 is a purely synthetic compound (a biaryl carbamate). It is not derived from cannabigerol and is produced by no plant or animal.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Enzyme inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

No dedicated article.

References

  1. Li W, Blankman JL, Cravatt BF. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J Am Chem Soc, 2007 (new tab)PMID 17629278
  2. Marrs WR et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci, 2010 (new tab)PMID 20657592
  3. Tchantchou F, Zhang Y. Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury. J Neurotrauma, 2013 (new tab)PMID 23151067
  4. Tanaka M et al. WWL70 attenuates PGE2 production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism. J Neuroinflammation, 2017 (new tab)PMID 28086912
  5. Wen J et al. WWL70 protects against chronic constriction injury-induced neuropathic pain in mice by cannabinoid receptor-independent mechanisms. J Neuroinflammation, 2018 (new tab)PMID 29310667
  6. Manterola A et al. Re-examining the potential of targeting ABHD6 in multiple sclerosis: efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis. Neuropharmacology, 2018 (new tab)PMID 30171986
  7. Shields CM et al. Biochemical and proteomic characterization of recombinant human α/β hydrolase domain 6. Sci Rep, 2019 (new tab)PMID 30696836
  8. PubChem, WWL70, CID 17759121 (identifiers and properties) (new tab)

Identifiers

Names

IUPAC name
[4-(4-carbamoylphenyl)phenyl] N-methyl-N-[(3-pyridin-4-ylphenyl)methyl]carbamate
Other names
WWL-70

Identifiers

Formula
C₂₇H₂₃N₃O₃
PubChem CID
17759121(new tab)
InChIKey
QTWNORFUQILKJL-UHFFFAOYSA-N
SMILES
CN(CC1=CC(=CC=C1)C2=CC=NC=C2)C(=O)OC3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.